Nurix Therapeutics, Inc. (NRIX) key performance indicators and operating metrics (1 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Objective Response Rate in Relapsed or Refractory Waldenström’s Macroglobulinemia (NX-5948) | 75.00 percent | FY2025-Q4 |
Back to NRIX overview · NRIX earnings · NRIX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.